Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Hunan Province Tumor Hospital is the lead sponsor of 32 current clinical trials in our China register. 25 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Anlotinib, Pemetrexed and Pembrolizumab. The most-studied condition is Non Small Cell Lung Cancer.

ClinicalTrials.gov trials by status

Recruiting2578%
Not yet open722%

Trials by phase

Phase 21856%
Observational825%
Phase 339%
Phase 1/226%
Phase 2/313%

Clinical trials sponsored by Hunan Province Tumor Hospital

32 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK NCT05266846 · ClinicalTrials.gov ↗ · ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy Drug: Pembrolizumab	Phase 2	Recruiting	2024-05	China
Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement NCT06073938 · ClinicalTrials.gov ↗ · Advanced Solid Tumors or Lymphomas	Observational	Recruiting	2022-09	China
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC NCT06348927 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drugs: Anlotinib, Sunvozertinib	Phase 2	Recruiting	2024-07	China
High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases NCT05379803 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drug: Furmonertinib	Phase 2	Recruiting	2022-05	China
Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy NCT05584267 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Recruiting	2022-12	China
Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer NCT05284539 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Drug: Pembrolizumab	Phase 2	Recruiting	2022-04	China
Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC NCT04324151 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Observational	Recruiting	2020-03	China
Survival Outcomes of Lung Cancer NCT03647098 · ClinicalTrials.gov ↗ · Lung Cancer	Observational	Recruiting	2018-08	China
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer NCT05059951 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Observational	Recruiting	2021-10	China
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer NCT04322617 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drug: Anlotinib	Phase 2/3	Recruiting	2020-03	China
Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer NCT07251582 · ClinicalTrials.gov ↗ · Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)	Phase 3	Recruiting	2026-08	China
Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC NCT04324125 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Observational	Recruiting	2020-03	China
A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer NCT05991193 · ClinicalTrials.gov ↗ · NSCLC	Observational	Recruiting	2023-12	China
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma NCT05014464 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Alectinib, Brigatinib, Carboplatin	Phase 2	Recruiting	2021-11	China
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW NCT06355609 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Anlotinib, Sunvozertinib	Phase 2	Recruiting	2024-07	China
The Efficacy and Safety of IBI363 in Solid Tumors NCT06081907 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Drug: IBI363	Phase 1/2	Recruiting	2023-12	China
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation NCT04322890 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation Drugs: Alectinib, Brigatinib, Crizotinib	Phase 2	Recruiting	2020-04	China
The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC. NCT04777084 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	2021-08	China
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC NCT04324164 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Egfr-Tki, Third-generation EGFR-TKI	Observational	Recruiting	2020-03	China
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC NCT06109558 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, RET Gene Mutation, MET Amplification Drug: Osimertinib	Phase 1/2	Recruiting	2023-12	China
Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases NCT06440954 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drug: Pemetrexed	Phase 2	Recruiting	2024-05	China
Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB NCT05295212 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Drug: Atezolizumab	Phase 2	Recruiting	2023-02	China
A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer NCT06183762 · ClinicalTrials.gov ↗ · Advanced Lung Cancer	Observational	Recruiting	2020-01	China
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors NCT05055908 · ClinicalTrials.gov ↗ · Lung Cancer Drugs: Pembrolizumab, Pemetrexed	Phase 3	Recruiting	2021-10	China
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer NCT04951947 · ClinicalTrials.gov ↗ · Small-cell Lung Cancer	Phase 2	Recruiting	2023-06	China
Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic NCT06497543 · ClinicalTrials.gov ↗ · Small-cell Lung Cancer Drug: Pemetrexed	Phase 2	Not yet open	2024-10	China
Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer NCT06828757 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 3	Not yet open	2025-05	China
Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction NCT06604351 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Not yet open	2024-09	China
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression NCT07001995 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC Drugs: Etoposide and carboplatin, Limertinib	Phase 2	Not yet open	2026-05	China
Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC NCT06706219 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer (Stage III) Drugs: Sacituzumab tirumotecan, Toripalimab	Phase 2	Not yet open	2026-05	China
Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases NCT06537297 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Not yet open	2024-09	China
Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance NCT06634667 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Anlotinib, Third-generation EGFR-TKI	Phase 2	Not yet open	2024-11	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Hunan Province Tumor Hospital trials

23 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Hunan Province Tumor Hospital trials

21 conditions

Non Small Cell Lung Cancer10 Non-small Cell Lung Cancer6 Non-Small Cell Lung Cancer5ALK Gene Mutation2Lung Cancer2 Small-cell Lung Cancer2 Lung Adenocarcinoma1 Immunotherapy1Advanced Solid Tumors or Lymphomas1Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)1Small Cell Lung Cancer1 Non Small Cell Lung Cancer NSCLC1 NSCLC1Non Small Cell Lung Cancer (Stage III)1Advanced Solid Tumor1EGFR Gene Mutation1ROS1 Gene Mutation1RET Gene Mutation1MET Amplification1EGF-R Positive Non-Small Cell Lung Cancer1Advanced Lung Cancer1

By trial register

Register	Trials	Recruiting
Clinical trials in China	32	25

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Non Small Cell Lung Cancer

Sponsor	Trials
MediLink Therapeutics (Suzhou)	4
Shanghai Henlius Biotech	4
Peking Union Medical College Hospital	4
Nuvation Bio	3
Guangdong Association of Clinical Trials	3
Verastem	2
OncoC4	2
HUYABIO International	2
N-Power Medicine	2
Tango Therapeutics	2

Sponsors with the most current trials registered for this condition.

Questions about Hunan Province Tumor Hospital trials

How many clinical trials does Hunan Province Tumor Hospital sponsor?

Hunan Province Tumor Hospital is the lead sponsor of 32 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Hunan Province Tumor Hospital trials recruiting?

Yes. 25 of its 32 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Hunan Province Tumor Hospital testing?

Its current trials name 23 drugs and biologicals as interventions. The most frequent are Anlotinib (4), Pemetrexed (4), Pembrolizumab (3), Alectinib (2) and Brigatinib (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Hunan Province Tumor Hospital clinical trials